Profile data is unavailable for this security.
About the company
CERo Therapeutics Holdings, Inc. is an immunotherapy company advancing the development of engineered T cell therapeutics for the treatment of cancer. The Company’s proprietary approach to T cell engineering, enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, which is designed to engage the body’s full immune repertoire to achieve optimized cancer therapy. Its cellular immunotherapy platform is focused on redirecting patient-derived T cells to eliminate tumors by building in engulfment pathways that employ phagocytic mechanisms to destroy cancer cells, creating CERo, which is referred to as chimeric engulfment receptor t cells (CER-T). The Company is initiating clinical trials for its lead product candidate, CER-1236, for hematological malignancies.
- Revenue in USD (TTM)0.00
- Net income in USD-2.54m
- Incorporated2021
- Employees8.00
- LocationCERo Therapeutics Holdings Inc201 Haskins Way, Suite 230SOUTH SAN FRANCISCO 94080United StatesUSA
- Phone+1 (215) 731-9450
- Fax+1 (302) 636-5454
- Websitehttps://www.phoenixbiotechacquisitioncorp.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lixte Biotechnology Holdings Inc | 0.00 | -4.03m | 4.14m | 3.00 | -- | -- | -- | -- | -1.83 | -1.83 | 0.00 | 0.9986 | 0.00 | -- | -- | 0.00 | -139.98 | -104.18 | -163.33 | -111.05 | -- | -- | -- | -- | -- | -563.88 | 0.00 | -- | -- | -- | 19.41 | -- | -- | -- |
| Oragenics Inc | 7.47k | -19.52m | 4.16m | 5.00 | -- | -- | -- | 556.41 | -6.99 | -6.99 | 0.0023 | 0.2377 | 0.0013 | -- | -- | 1,494.00 | -349.31 | -97.60 | -451.26 | -106.24 | -- | -- | -261,261.60 | -36,169.75 | -- | -- | 0.00 | -- | -71.37 | -- | -44.56 | -- | 51.64 | -- |
| Creative Medical Technology Holdings Inc | 17.00k | -5.73m | 4.16m | 4.00 | -- | 0.5466 | -- | 244.80 | -4.07 | -4.07 | 0.012 | 5.69 | 0.0015 | 1.00 | -- | 4,250.00 | -51.83 | -110.00 | -53.71 | -- | 60.00 | 65.82 | -33,716.41 | -7,961.14 | 20.20 | -- | 0.00 | -- | -89.84 | -40.86 | 47.88 | -- | -- | -- |
| Synaptogenix Inc | 0.00 | -3.45m | 4.28m | 5.00 | -- | 0.2175 | -- | -- | -3.89 | -3.89 | 0.00 | 14.99 | 0.00 | -- | -- | 0.00 | -5.54 | -40.33 | -6.89 | -43.36 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -142.17 | -- | -3.21 | -- |
| Galera Therapeutics Inc | 0.00 | -29.11m | 4.30m | 7.00 | -- | -- | -- | -- | -0.5892 | -0.5892 | 0.00 | -2.54 | 0.00 | -- | -- | 0.00 | -90.03 | -83.69 | -119.01 | -97.54 | -- | -- | -- | -- | -- | -14.34 | 11.60 | -- | -- | -- | 5.05 | -- | -29.84 | -- |
| Enveric Biosciences Inc | 0.00 | -10.59m | 4.38m | 7.00 | -- | 0.7155 | -- | -- | -3.67 | -3.67 | 0.00 | 0.6862 | 0.00 | -- | -- | 0.00 | -133.67 | -104.94 | -206.10 | -156.88 | -- | -- | -- | -243.54 | -- | -- | 0.00 | -- | -- | -- | 7.14 | -- | -- | -- |
| CERo Therapeutics Holdings Inc | 0.00 | -2.54m | 4.47m | 8.00 | -- | -- | -- | -- | -0.3796 | -0.3796 | 0.00 | -0.9226 | 0.00 | -- | -- | 0.00 | -9.96 | -- | -33.80 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -279.82 | -- | -- | -- |
| Alaunos Therapeutics Inc | 7.00k | -19.13m | 4.52m | 1.00 | -- | 1.20 | -- | 645.08 | -11.95 | -11.95 | 0.0044 | 2.36 | 0.0004 | -- | 1.75 | 7,000.00 | -117.34 | -74.83 | -143.58 | -89.57 | -- | -- | -273,271.40 | -10,508.06 | -- | -- | 0.00 | -- | -99.83 | -49.08 | 6.86 | -- | -15.56 | -- |
| Palisade Bio Inc | 0.00 | -14.17m | 4.54m | 9.00 | -- | 0.3721 | -- | -- | -20.07 | -20.07 | 0.00 | 10.30 | 0.00 | -- | -- | 0.00 | -90.97 | -132.36 | -109.07 | -165.45 | -- | -- | -- | -27,892.32 | -- | -972.73 | 0.0339 | -- | -- | -0.7814 | 13.74 | -- | 18.53 | -- |
| ProtoKinetix, Inc. | 0.00 | -369.97k | 4.56m | 0.00 | -- | 11.25 | -- | -- | -0.0011 | -0.0011 | 0.00 | 0.0012 | 0.00 | -- | -- | -- | -78.67 | -696.88 | -85.20 | -785.51 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 78.22 | -- | 10.78 | -- |
| Azitra Inc | 408.20k | -9.96m | 4.57m | 10.00 | -- | 0.3332 | -- | 11.19 | -12.12 | -12.12 | 0.1151 | 1.80 | 0.0595 | -- | 1.83 | 40,820.00 | -145.30 | -- | -194.72 | -- | -- | -- | -2,440.46 | -- | -- | -- | 0.0191 | -- | 141.55 | -- | 6.02 | -- | -- | -- |
| Notable Labs Ltd | 313.00k | -16.74m | 4.62m | 16.00 | -- | 0.6425 | -- | 14.75 | -2.47 | -2.47 | 0.046 | 0.7439 | 0.0176 | -- | -- | 19,562.50 | -93.89 | -52.02 | -120.26 | -62.09 | 37.70 | 60.19 | -5,346.97 | -3,636.93 | -- | -- | 0.0405 | -- | -52.89 | -11.93 | 65.13 | -- | -50.69 | -- |
| Qualigen Therapeutics Inc | 0.00 | -9.27m | 4.80m | 4.00 | -- | -- | -- | -- | -1.66 | -1.75 | 0.00 | -0.445 | 0.00 | -- | -- | 0.00 | -134.64 | -- | -- | -- | -- | -- | -- | -- | -- | -9.64 | -- | -- | -- | -- | 10.22 | -- | -- | -- |
Data as of Sep 20 2024. Currency figures normalised to CERo Therapeutics Holdings Inc's reporting currency: US Dollar USD
0.97%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Arena Investors LPas of 30 Jun 2024 | 198.57k | 0.39% |
| Avantax Planning Partners, Inc.as of 30 Jun 2024 | 80.00k | 0.16% |
| Fifth Lane Capital LPas of 30 Jun 2024 | 76.59k | 0.15% |
| Geode Capital Management LLCas of 30 Jun 2024 | 48.14k | 0.09% |
| Jane Street Capital LLCas of 30 Jun 2024 | 32.04k | 0.06% |
| Two Sigma Investments LPas of 30 Jun 2024 | 18.10k | 0.04% |
| Corient Private Wealth LLCas of 30 Jun 2024 | 15.00k | 0.03% |
| Birchview Capital LPas of 30 Jun 2024 | 12.97k | 0.03% |
| HRT Financial LLCas of 30 Jun 2024 | 11.94k | 0.02% |
| FNY Capital Management LPas of 30 Jun 2024 | 5.25k | 0.01% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
